<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055557</url>
  </required_header>
  <id_info>
    <org_study_id>ZDHMWHA</org_study_id>
    <nct_id>NCT05055557</nct_id>
  </id_info>
  <brief_title>The Role and Mechanism of O-GlcNAc Glycosylation Modified HAS2 in the Hyaluronic Acid Synthesis in ARDS</brief_title>
  <official_title>The Role and Mechanism of O-GlcNAc Glycosylation Modified HAS2 in the Hyaluronic Acid Synthesis in ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintaining the normal function of the pulmonary microvascular barrier is critical for ARDS&#xD;
      treatment. To assess the relationship between the HAS2 protein level, HA content and the&#xD;
      clinical prognosis of ARDS in patients with ARDS. Compare the HAS2 protein levels, HMW-HA and&#xD;
      LMW-HA levels, endothelial injury indicators, and lungs in the blood of severe and non-ARDS&#xD;
      severe patients and healthy adults admitted to the ICU. The correlation between permeability,&#xD;
      disease severity and prognosis to explore the predictability of HAS2-HA on the clinical&#xD;
      outcome of ARDS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>28-day fatality Rate</measure>
    <time_frame>28 days after enrollment</time_frame>
    <description>28-day mortality (patients will be followed for 28 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90-day fatality rate</measure>
    <time_frame>90 days after enrollment</time_frame>
    <description>90-day mortality (patients will be followed for 90 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU hospital stay</measure>
    <time_frame>through study completion, an average of 4 week</time_frame>
    <description>Length of ICU stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU fatality rate</measure>
    <time_frame>through study completion, an average of 4 week</time_frame>
    <description>The ratio of the total number of deaths from all causes of the enrolled patients during ICU hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wearing time from mechanical ventilation</measure>
    <time_frame>through study completion，an average of 4 week</time_frame>
    <description>successful weaning defined as the absence of the requirement for ventilatory support, without reintubation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral blood HMW-HA and LMW-HA levels</measure>
    <time_frame>0, 1, 3, 7 days after enrollment</time_frame>
    <description>ELISA method to separate and detect HMW-HA and LMW-HA levels（Units of Measure unit nM/ml）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HAS2 protein content in peripheral blood</measure>
    <time_frame>0, 1, 3, 7 days after enrollment</time_frame>
    <description>ELISA method detects HAS2 protein in peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ENOS, ET-1, vWF levels in peripheral blood</measure>
    <time_frame>0, 1, 3, 7 days after enrollment</time_frame>
    <description>ELISA method to detect eNOS, ET-1, vWF in peripheral blood to evaluate endothelial cell damage（Measure unit ng/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of bound mucinoglycans-1, nitric oxide, and acetylheparin sulfate in peripheral blood</measure>
    <time_frame>0, 1, 3, 7 days after enrollment</time_frame>
    <description>glycocalyx levels of the endothelium were assessed by measuring the levels of mucin polysaccharide-1, nitric oxide and acetyl heparan sulfate in peripheral blood by ELISA assay（Measure unit ng/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In peripheral blood, IL-1α, IL-6, neutrophils, lymphocytes, descending Procalcin, C-reactive protein value</measure>
    <time_frame>0, 1, 3, 7 days after enrollment</time_frame>
    <description>The ELISA method detects IL-1α and IL-6 in the blood, and records the blood neutrophils, lymphocytes, and vary in procalcin and C-reactive protein to assess the inflammatory response of ARDS(Measure unit pg/ml）</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyaluronic Acid</condition>
  <arm_group>
    <arm_group_label>ARDS group</arm_group_label>
    <description>1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).&#xD;
3.Diagnosis of ARDS less than 72 hours. 4.Just observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Critically ill patients without ARDS group</arm_group_label>
    <description>Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy adult group</arm_group_label>
    <description>Healthy adults, voluntarily join the study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task&#xD;
        Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200&#xD;
        mmHg with a PEEP ≥5 cmH2O).&#xD;
&#xD;
        3.Diagnosis of ARDS less than 72 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task&#xD;
        Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200&#xD;
        mmHg with a PEEP ≥5 cmH2O).&#xD;
&#xD;
        3.Diagnosis of ARDS less than 72 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All patients who meet any of the following criteria will be excluded at enrollment and&#xD;
        randomization.&#xD;
&#xD;
          1. Severe chronic respiratory diseases requiring long-term home oxygen therapy or&#xD;
             noninvasive MV.&#xD;
&#xD;
          2. Undrained pneumothorax or subcutaneous emphysema.&#xD;
&#xD;
          3. Severe neuromuscular disease.&#xD;
&#xD;
          4. Hemodynamic instability (&gt;30% increase in vasopressors within 6 hours or&#xD;
             norepinephrine &gt;0.5 ug/kg/min) (Am J Respir Crit Care Med. 2020; 201(2):178-187) .&#xD;
&#xD;
          5. Contraindications to hypercapnia, such as intracranial hypertension or acute coronary&#xD;
             syndrome.&#xD;
&#xD;
          6. Severe other organs dysfunction with a low expected survival (7 days) or palliative&#xD;
             care.&#xD;
&#xD;
          7. Solid organ or hematologic tumors with the expected survival time less than 30 days.&#xD;
&#xD;
          8. Participating in other clinical trials within 30 days.&#xD;
&#xD;
          9. Pregnancy.&#xD;
&#xD;
         10. Refusal to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Ling Liu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Acute respiratory distress syndrome</keyword>
  <keyword>Pulmonary microvascular endothelial barrier;</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Hyaluronic acid synthase 2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

